Pulsar-wind nebulae and magnetar outflows: observations at radio, X-ray, and gamma-ray wavelengths

We review observations of several classes of neutron-star-powered outflows: pulsar-wind nebulae (PWNe) inside shell supernova remnants (SNRs), PWNe interacting directly with interstellar medium (ISM), and magnetar-powered outflows. We describe radio, X-ray, and gamma-ray observations of PWNe, focusing first on integrated spectral-energy distributions (SEDs) and global spectral properties. High-resolution X-ray imaging of PWNe shows a bewildering array of morphologies, with jets, trails, and other structures. Several of the 23 so far identified magnetars show evidence for continuous or sporadic emission of material, sometimes associated with giant flares, and a few possible "magnetar-wind nebulae" have been recently identified.Comment: 61 pages, 44 figures (reduced in quality for size reasons). Published in Space Science Reviews, "Jets and Winds in Pulsar Wind Nebulae, Gamma-ray Bursts and Blazars: Physics of Extreme Energy Release

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Preparation and characterization of the bacterial cellulose/polyurethane nanocomposites

New nanocomposites based on bacterial cellulose nanofibers (BCN) and polyurethane (PU) prepolymer were prepared and characterized by SEM, FT-IR, XRD, and TG/DTG analyses. An improvement of the interface reaction between the BCN and the PU prepolymer was obtained by a solvent exchange process. FT-IR results showed the main urethane band at 2,270 cm-1 to PU prepolymer; however, in nanocomposites new bands appear as disubstituted urea at 1,650 and 1,550 cm-1. In addition, the observed decrease in the intensity of the hydroxyl band (3,500 cm-1) suggests an interaction between BCN hydroxyls and NCO-free groups. The nanocomposites presented a non-crystalline character, significant thermal stability (up to 230 °C) and low water absorption when compared to pristine BCN. © 2013 Akadémiai Kiadó, Budapest, Hungary

On the Manifold Structure of the Space of Brain Images

Abstract. This paper investigates an approach to model the space of brain images through a low-dimensional manifold. A data driven method to learn a manifold from a collections of brain images is proposed. We hypothesize that the space spanned by a set of brain images can be captured, to some approximation, by a low-dimensional manifold, i.e. a parametrization of the set of images. The approach builds on recent advances in manifold learning that allow to uncover nonlinear trends in data. We combine this manifold learning with distance measures between images that capture shape, in order to learn the underlying structure of a database of brain images. The proposed method is generative. New images can be created from the manifold parametrization and existing images can be projected onto the manifold. By measuring projection distance of a held out set of brain images we evaluate the fit of the proposed manifold model to the data and we can compute statistical properties of the data using this manifold structure. We demonstrate this technology on a database of 436 MR brain images.

Mean Template for Tensor-Based Morphometry using Deformation Tensors

Abstract. Tensor-based morphometry (TBM) studies anatomical differences between brain images statistically, to identify regions that differ between groups, over time, or correlate with cognitive or clinical measures. Using a nonlinear registration algorithm, all images are mapped to a common space, and statistics are most commonly performed on the Jacobian determinant (local expansion factor) of the deformation fields. In [14], it was shown that the detection sensitivity of the standard TBM approach could be increased by using the full deformation tensors in a multivariate statistical analysis. Here we set out to improve the common space itself, by choosing the shape that minimizes a natural metric on the deformation tensors from that space to the population of control subjects. This method avoids statistical bias and should ease nonlinear registration of new subjects data to a template that is ’closest ’ to all subjects’ anatomies. As deformation tensors are symmetric positive-definite matrices and do not form a vector space, all computations are performed in the log-Euclidean framework [1]. The control brain B that is already the closest to ’average ’ is found. A gradient descent algorithm is then used to perform the minimization that iteratively deforms this template and obtains the mean shape. We apply our method to map the profile of anatomical differences in a dataset of 26 HIV/AIDS patients and 14 controls, via a log-Euclidean Hotelling’s T 2 test on the deformation tensors. These results are compared to the ones found using the ’best ’ control, B. Statistics on both shapes are evaluated using cumulative distribution functions of the pvalues in maps of inter-group differences.

P.: Mean template for tensor-based morphometry using deformation tensors

Abstract. Tensor-based morphometry (TBM) studies anatomical differences between brain images statistically, to identify regions that differ between groups, over time, or correlate with cognitive or clinical measures. Using a nonlinear registration algorithm, all images are mapped to a common space, and statistics are most commonly performed on the Jacobian determinant (local expansion factor) of the deformation fields. In [14], it was shown that the detection sensitivity of the standard TBM approach could be increased by using the full deformation tensors in a multivariate statistical analysis. Here we set out to improve the common space itself, by choosing the shape that minimizes a natural metric on the deformation tensors from that space to the population of control subjects. This method avoids statistical bias and should ease nonlinear registration of new subjects data to a template that is ’closest ’ to all subjects’ anatomies. As deformation tensors are symmetric positive-definite matrices and do not form a vector space, all computations are performed in the log-Euclidean framework [1]. The control brain B that is already the closest to ’average ’ is found. A gradient descent algorithm is then used to perform the minimization that iteratively deforms this template and obtains the mean shape. We apply our method to map the profile of anatomical differences in a dataset of 26 HIV/AIDS patients and 14 controls, via a log-Euclidean Hotelling’s T 2 test on the deformation tensors. These results are compared to the ones found using the ’best ’ control, B. Statistics on both shapes are evaluated using cumulative distribution functions of the p-values in maps of inter-group differences.